Skip to main content
. 2021 Jul 15;17(7):e1009544. doi: 10.1371/journal.ppat.1009544

Fig 3. Protection in the human ACE2 transgenic mouse model.

Fig 3

BAL from vector-treated animals analyzed for: A. decoy protein by MS; B. SARS-CoV-2 spike ELISA; C. neutralization of SARS-CoV-2 pseudotyped lentivirus. D. Challenge study design. E. Weight loss in the animals that were sustained for 7 days; one animal in the vehicle and vector treated groups required euthanasia. F. MS assay of expression in ASF (corrected for BAL dilution). G. Pulmonary inflammation histopathology scores of tissues harvested at days 4 and 7. H. Viral RNA in BAL. I. Viral RNA in lung. J. Sub-genomic RNA in lung. Outliers are indicated with X.